SDC1 and Miyoshi myopathy: The significant clinical outcomes of anti-CD19 CAR-T cells in MM justified the creation of CAR-T cells targeting other antigens expressed on myeloma cells, including CD38 (83), CD138 (84), SLAMF7 (85), SLAMF3 (86), CD56 (87), NKG2D (88), and most successfully BCMA (89).